1
|
β-Blocking Properties of Propafenone in Extensive Oxidisers: A Study on Heart Rate Behaviour during Holter Monitoring. ACTA ACUST UNITED AC 2012. [DOI: 10.1007/bf03259424] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
2
|
Boriarti G, Strocchi E, Capucci A, Boschi S, Marchesini B, Ambrosioni E, Magnani B. Relationships Between Debrisoquine Hydroxylation and Propafenone Pharmacokinetics. ACTA ACUST UNITED AC 2012. [DOI: 10.1007/bf03258249] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
3
|
Lee EJ, Ang SB. Measurement of debrisoquine and 4-hydroxydebrisoquine in urine by liquid chromatography. J Pharm Biomed Anal 2009; 5:435-9. [PMID: 16867515 DOI: 10.1016/0731-7085(87)80052-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/1987] [Revised: 03/03/1987] [Indexed: 11/30/2022]
Affiliation(s)
- E J Lee
- Department of Pharmacology, National University of Singapore, 10 Kent Ridge Crescent, Singapore
| | | |
Collapse
|
4
|
Solai LK, Pollock BG, Mulsant BH, Frye RF, Miller MD, Sweet RA, Kirshner M, Sorisio D, Begley A, Reynolds CF. Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients. J Clin Psychopharmacol 2002; 22:481-6. [PMID: 12352271 DOI: 10.1097/00004714-200210000-00007] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
This study was performed in elderly patients (1) to assess the degree to which CYP2D6 mediated metabolism of debrisoquine at baseline determines plasma concentration to dose quotients for nortriptyline or paroxetine after 4 weeks of treatment, and (2) to compare the effects of nortriptyline and paroxetine on debrisoquine metabolism after 6 weeks of treatment. CYP2D6 activity was estimated in 66 subjects (71.4 +/- 7.2 years) before initiating treatment and again after 6 weeks of treatment with either nortriptyline or paroxetine under randomized, double-blind conditions according to a standard protocol. CYP2D6 activity was estimated by the debrisoquine recovery ratio in a 6- to 8-hour urine sample collected after oral administration of 10 mg debrisoquine sulfate. Nortriptyline and paroxetine plasma concentrations were obtained weekly. Baseline debrisoquine recovery ratio values were significantly correlated with the plasma concentration to dose quotient at 4 weeks for both nortriptyline ( = -0.75, = 0.0001, N = 29) and paroxetine ( = -0.50, = 0.003, N = 33). Treatment with either nortriptyline or paroxetine was associated with a significant decrease in the median debrisoquine recovery ratio, reflecting inhibition of CYP2D6 metabolism. The percent decrease associated with nortriptyline was significantly smaller than that with paroxetine ( < 0.0001). None of the patients treated with nortriptyline but 19 of the 32 extensive metabolizers treated with paroxetine were converted to phenotypic poor metabolic status. Our observations of CYP2D6 inhibition are consistent with data and results obtained in younger healthy volunteers. The significant correlations between baseline debrisoquine recovery ratio and the plasma concentrations to dose quotients at 4 weeks for both nortriptyline and paroxetine are consistent with CYP2D6 playing a major role in the metabolism of both drugs. CYP2D6 inhibition by paroxetine, which effectively converted 59% of patients to phenotypic PMs, may be especially relevant for elderly patients given their generally higher concentration of paroxetine.
Collapse
Affiliation(s)
- LalithKumar K Solai
- Mental Health Intervention Research Center for the Study of Late-Life Mood Disorders, University of Pittsburgh School of Medicine, Pennsylvania, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Lanz M, Theurillat R, Thormann W. Characterization of stereoselectivity and genetic polymorphism of the debrisoquine hydroxylation in man via analysis of urinary debrisoquine and 4-hydroxydebrisoquine by capillary electrophoresis. Electrophoresis 1997; 18:1875-81. [PMID: 9372283 DOI: 10.1002/elps.1150181025] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Using capillary zone electrophoresis with a phosphate buffer at pH 2.5 containing 50 mM heptakis-(2,3,6-tri-O-methyl)-beta-CD as chiral selector, the separation of the enantiomers of the main metabolite of debrisoquine (DEB), 4-hydroxydebrisoquine (4-OHDEB), is reported. For extraction of underivatized urinary DEB, S-4-OHDEB and R-4-OHDEB, a procedure using disposable cartridges containing a polystyrene-based polymer was developed. A few nL of the extracts were analyzed in a 60 cm fused-silica capillary of 50 microns ID and solute detection was effected at 195 nm. For all three compounds, a mean (n = 5) recovery of about 73% and a detection limit of about 150 ng/mL were noted. Data obtained with urines that were received for routine phenotyping with DEB and mephenytoin confirmed the almost exclusive formation of S-4-OHDEB. Under the described conditions, no R-4-OHDEB could be detected. With these data and those obtained employing no chiral selector in the buffer, differentiation between extensive metabolizer phenotypes (EM) and poor metabolizer phenotypes (PM) for DEB was unambiguously possible by the presence of a significant peak and no (or minor) peak for 4-OHDEB, respectively. Data obtained for ten EM subjects and five PM subjects were found to agree with those generated by the routine assay based on gas chromatography. The capillary electrophoretic assays described are simple, reproducible (relative standard deviation of peak area ratios < 3%), require no sample derivatization, consume no halogenated organic solvents, and operate with inexpensive separation columns as well as small amounts of chemicals.
Collapse
Affiliation(s)
- M Lanz
- Department of Clinical Pharmacology, University of Bern, Switzerland
| | | | | |
Collapse
|
6
|
Cifuentes A, Valencia J, Sanz E, Sánchez MJ, Rodríguez-Delgado MA. Separation and quantitation of debrisoquine and 4-hydroxydebrisoquine in human urine by capillary electrophoresis and high-performance liquid chromatography. J Chromatogr A 1997; 778:389-96. [PMID: 9299748 DOI: 10.1016/s0021-9673(97)00285-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
A comparative study on the use of reversed-phase high-performance liquid chromatography (RP-HPLC) and capillary electrophoresis (CE) for the determination of debrisoquine (D) and its metabolite, 4-hydroxydebrisoquine (4-HD), in human urine is presented. Four different urine pre-treatments are compared for purification of samples prior to their injection in HPLC and CE. The use of a solid-phase extraction with a C18 cartridge provides the best results for the urine sample treatment, with good recoveries, i.e., 94.5% for D and 93.4% for 4-HD, and high reproducibility, i.e., R.S.D. N = 10 values of 1.7% and 1.2%, respectively. Under our separation conditions it is shown that CE is twice as fast and provides slightly better analysis time reproducibility than HPLC for this type of sample. Both the sensitivity and peak area reproducibility are better when HPLC is used. The two techniques show good agreement when employed for determination of phenotypes for hydroxylation, which seems to corroborate the usefulness of CE for this type of study.
Collapse
Affiliation(s)
- A Cifuentes
- Departamento de Química Analítica, Nutrición y Bromatología, Universidad de La Laguna, Tenerife, Spain
| | | | | | | | | |
Collapse
|
7
|
Abstract
All available antidepressants with the exception of fluvoxamine and nefazodone either are metabolized by cytochrome P450 2D6 (CYP2D6) and/or inhibit this isozyme. To date, nothing in this regard has been published concerning bupropion. We report that plasma level/dose ratios for bupropion, and its metabolites erythrohydrobupropion and threohydrobupropion, were not associated with debrisoquine metabolic status in 12 patients, three of whom were poor 2D6 metabolizers. The plasma level/dose ratios for the metabolite hydroxybupropion were, however, significantly higher in poor 2D6 metabolizers. In three patients, who received a second phenotyping test during treatment with bupropion, debrisoquine metabolic ratios were not increased. It is thus inferred that bupropion is neither metabolized by nor inhibits CYP2D6. The potential accumulation of hydroxybupropion after CYP2D6 inhibition may, however, contribute to toxicity and impair bupropion's therapeutic effectiveness.
Collapse
Affiliation(s)
- B G Pollock
- Department of Psychiatry, University of Pittsburgh School of Medicine, Pennsylvania, USA
| | | | | | | |
Collapse
|
8
|
Frye RF, Branch RA. Improved high-performance liquid chromatographic determination of debrisoquine and 4-hydroxydebrisoquine in human urine following direct injection. JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL APPLICATIONS 1996; 677:178-82. [PMID: 8925093 DOI: 10.1016/0378-4347(95)00380-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
A sensitive and specific reversed-phase high-performance liquid chromatographic assay was developed for the determination of debrisoquine and 4-hydroxydebrisoquine in urine. The urine samples were directly injected following an ether clean-up step which eliminated interference. Separation of the analytes was achieved using a mobile phase consisting of acetonitrile-methanol-0.02 M heptane sulfonic acid (pH 3.0) (6:37:57) and a mu Bondapak C18 analytical column. The assay utilizes fluorescence detection at 208 nm (ex) and 562 (em). The within-day and between-day coefficients of variation were < or = 10% for both components and accuracy was within 12%. The method is suitable of pharmacogenetic studies utilizing debrisoquine.
Collapse
Affiliation(s)
- R F Frye
- Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, PA 15261, USA
| | | |
Collapse
|
9
|
Kunicki PK, Sitkiewicz D, Pawlik A, Bielicka-Sulzyc V, Borowiecka E, Gawrońska-Szklarz B, Sterna R, Matsumoto H, Radziwoń-Zaleska M. Debrisoquine hydroxylation in a Polish population. Eur J Clin Pharmacol 1995; 47:503-5. [PMID: 7768252 DOI: 10.1007/bf00193702] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The genetic polymorphism of drug oxidation mediated by cytochrome P450IID6 (CYP2D6) was determined in 154 Polish volunteers using debrisoquine as the test substance. The results showed a bimodal distribution of the debrisoquine metabolic ratio (MR). Nine persons (5.8%) with MR > 12.6 were classified as poor metabolisers (gene frequency 0.242), which is in substantial agreement with the data reported for other Caucasian populations.
Collapse
Affiliation(s)
- P K Kunicki
- Department of Clinical Biochemistry, National Institute of Cardiology, Warszawa, Poland
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Hals PA, Dahl SG. Effect of levomepromazine and metabolites on debrisoquine hydroxylation in the rat. PHARMACOLOGY & TOXICOLOGY 1994; 75:255-60. [PMID: 7870695 DOI: 10.1111/j.1600-0773.1994.tb00357.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The influence of the major metabolites of the phenothiazine derivative, levomepromazine (methotrimeprazine), on hydroxylation of debrisoquine was examined in male Sprague-Dawley rats. The metabolic ratio of debrisoquine/4-hydroxy debrisoquine was first determined in rats after oral administration of 10 mg/kg of debrisoquine. Then the same dose of debrisoquine was co-administered with various doses of levomepromazine or one of its metabolites. Levomepromazine and its sulphoxidated, N-demethylated and O-demethylated metabolites caused highly significant and dose-dependent increases in the debrisoquine metabolic ratio. 3-Hydroxy levomepromazine had no significant effect on the metabolism of debrisoquine. This indicates that the non-hydroxylated metabolites of levomepromazine have relatively high affinities for the cytochrome P450 enzyme which converts debrisoquine to 4-hydroxy debrisoquine in the rat. Such metabolites may therefore be responsible for a considerable part of the inhibitory effect of debrisoquine hydroxylation previously reported in patients treated with phenothiazine neuroleptics.
Collapse
Affiliation(s)
- P A Hals
- Department of Pharmacology, University of Tromsø, Norway
| | | |
Collapse
|
11
|
Bozkurt A, Basci NE, Isimer A, Kayaalp SO. Determination of debrisoquine and 4-hydroxydebrisoquine in urine by high-performance liquid chromatography with fluorescence detection after solid-phase extraction. J Pharm Biomed Anal 1993; 11:745-9. [PMID: 8257740 DOI: 10.1016/0731-7085(93)80184-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
A simple, selective and sensitive method has been developed to determine debrisoquine and 4-hydroxydebrisoquine in human urine. Separation of the analytes was obtained using a mobile phase of 0.1 M sodium dihydrogen phosphate-acetonitrile (87:13, v/v) and a muBondapak C18 column. The column effluent was monitored with fluorescence detection at 210 nm (ex) and 290 nm (em). Rapid sample preparation was achieved by solid-phase extraction columns (Bond Elut CBA, 3 ml capacity) which provided excellent recovery values for both compounds. The cost per sample using this approach could be minimized by column regeneration and re-use. The within-day and the day-to-day reproducibilities were less than 7% for both components. The method was shown to be suitable for the study of the debrisoquine-sparteine type genetic polymorphism in man.
Collapse
Affiliation(s)
- A Bozkurt
- Department of Pharmacology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
| | | | | | | |
Collapse
|
12
|
Pollock BG, Perel JM. Phenotypes for psychotropic drug metabolism in the elderly. PSYCHOPHARMACOLOGY SERIES 1993; 10:238-45. [PMID: 8361978 DOI: 10.1007/978-3-642-78010-3_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Affiliation(s)
- B G Pollock
- Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, PA 15213
| | | |
Collapse
|
13
|
Goubier C, Girard I, Ferry S. High-performance liquid chromatographic assay of debrisoquine and its 4-hydroxy metabolite in human urine. Chromatographia 1991. [DOI: 10.1007/bf02327897] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
14
|
Daumas L, Sabot JF, Vermeulen E, Clapot P, Allegre F, Pinatel H, Boucherat M, Francois B. Determination of debrisoquine and metabolites in human urine by gas chromatography-mass spectrometry. JOURNAL OF CHROMATOGRAPHY 1991; 570:89-97. [PMID: 1797839 DOI: 10.1016/0378-4347(91)80203-o] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
A gas chromatographic-mass spectrometric analysis has been developed for the determination of debrisoquine and its metabolites in the urine of healthy individuals (controls) and patients with chronic renal failure. The sensitive and specific assay comprises selected-ion monitoring of the drug and the metabolites 4-hydroxydebrisoquine and 8-hydroxydebrisoquine using guanoxan as the internal standard. The limit of detection is ca. 0.2 microgram/ml. The clinical study shows that the healthy individuals and patients with chronic renal failure can be divided in two groups of extensive metabolizers and poor metabolizers, respectively. The extensive metabolizers excreted large amounts of 4-hydroxydebrisoquine and minor amounts of 8-hydroxydebrisoquine. The poor metabolizers excreted small amounts of 4-hydroxy metabolite, and no 8-hydroxydebrisoquine was detected in the urine.
Collapse
Affiliation(s)
- L Daumas
- Laboratoire de Chimie Analytique II, Faculté de Pharmacie, Lyon, France
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Boriani G, Strocchi E, Capucci A, Callivà R, Frabetti L, Ambrosioni E, Magnani B. Flecainide: evidence of non-linear kinetics. Eur J Clin Pharmacol 1991; 41:57-9. [PMID: 1782978 DOI: 10.1007/bf00280107] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The pharmacokinetics of flecainide has been studied in 12 patients with ventricular arrhythmias, both after single administration and during chronic treatment. Both the half-life and the AUC were significantly increased during chronic treatment. This suggests that the kinetics of flecainide might be non-linear also in patients with normal kidney and liver function. The increase in plasma flecainide levels during chronic treatment could not be predicted, so close monitoring of its plasma levels is advisable.
Collapse
Affiliation(s)
- G Boriani
- Institute of Cardiovascular Diseases, University of Bologna, Italy
| | | | | | | | | | | | | |
Collapse
|
16
|
Schwende FJ, Rykert UM. Determination of alentamol hydrobromide, a novel antipsychotic agent, in human blood plasma and urine by high-performance liquid chromatography with fluorescence detection and solid-phase extraction. JOURNAL OF CHROMATOGRAPHY 1991; 565:488-96. [PMID: 1874898 DOI: 10.1016/0378-4347(91)80415-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Alentamol hydrobromide, (+)-2-(dipropylamino)-2,3-dihydro-1H-phenalen-5-ol monohydrobromide, is a selective dopamine agonist currently being investigated for the treatment of schizophrenia. This paper describes a reversed-phase high-performance liquid chromatographic-based method for the quantification of alentamol in blood plasma and urine. The method utilizes solid-phase extraction with carboxylic acid-derivatized silica columns. A limit of quantitation of 0.1 ng/ml in plasma was achieved by virtue of selective extraction and fluorescence detection. Example chromatograms of plasma and urine specimens from clinical trials demonstrate the utility of the method.
Collapse
Affiliation(s)
- F J Schwende
- Drug Metabolism Research, Upjohn Company, Kalamazoo, MI 49001
| | | |
Collapse
|
17
|
Huober J, Bertram B, Petru E, Kaufmann M, Schmähl D. Metabolism of debrisoquine and susceptibility to breast cancer. Breast Cancer Res Treat 1991; 18:43-8. [PMID: 1854978 DOI: 10.1007/bf01975442] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
There may exist an association between the genetically determined oxidation status of the antihypertensive agent debrisoquine (DEB) and the propensity to develop tumours. The metabolism of DEB is extensive in 90% of healthy subjects (metabolic ratio = MR = 0-12.6; MR = % DEB excreted divided by % 4-hydroxy-DEB excreted) and poor in 10% (MR greater than 12.6). In patients with cancer of the lung, urinary bladder, and gastrointestinum, the percentage of high metabolizers is increased to greater than 98%. The poor metabolizer mode is almost devoid of cancer patients. It was investigated whether breast cancer patients show a similar association with respect to the oxidative status of DEB. 108 breast cancer patients and 123 women with benign gynecologic disorders received 1 tablet of 10 mg DEB orally in the evening. Urine was collected for the subsequent 8 hrs and analysed for its content of DEB and its main urinary metabolite 4-OH-DEB by means of HPLC. No decreased amount of poor metabolizers was seen in the cancer group.
Collapse
Affiliation(s)
- J Huober
- Institute of Toxicology and Chemotherapy, German Cancer Research Center, Heidelberg
| | | | | | | | | |
Collapse
|
18
|
Sakai H, Kobayashi S, Hamada K, Iida S, Akita H, Tanaka E, Uchida E, Yasuhara H. The effects of diltiazem on hepatic drug metabolizing enzymes in man using antipyrine, trimethadione and debrisoquine as model substrates. Br J Clin Pharmacol 1991; 31:353-5. [PMID: 2054276 PMCID: PMC1368366 DOI: 10.1111/j.1365-2125.1991.tb05543.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Six healthy male subjects were given single oral doses of antipyrine (7 mg kg-1), trimethadione (4 mg kg-1) and debrisoquine (10 mg) before and during diltiazem treatment (30 mg three times daily orally for 8 days). Antipyrine clearance decreased from 33.7 +/- 9.1 to 22.5 +/- 4.9 ml min-1 (P less than 0.05, mean +/- s.e. mean) after diltiazem treatment without any significant change in apparent volume of distribution (0.59 +/- 0.06 to 0.60 +/- 0.04 1 kg-1), resulting in an increase in antipyrine elimination half-life from 13.4 +/- 4.8 to 19.7 +/- 3.2 h (P less than 0.05). The formation clearance of antipyrine to 4-hydroxyantipyrine was decreased significantly from 10.8 +/- 2.7 to 6.6 +/- 2.7 ml min-1 (P less than 0.05), while that to 3-hydroxymethylantipyrine and norantipyrine was not altered by diltiazem. The metabolic ratio of debrisoquine (urinary excretion of debrisoquine/4-hydroxydebrisoquine) was increased significantly from 0.70 +/- 0.05 to 1.95 +/- 0.20 (P less than 0.05), while that of trimethadione (serum concentration of dimethadione/trimethadione) was not changed significantly (0.48 +/- 0.08 vs 0.41 +/- 0.06) after diltiazem treatment. Diltiazem selectively inhibits cytochrome P-450 isoenzymes.
Collapse
Affiliation(s)
- H Sakai
- Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan
| | | | | | | | | | | | | | | |
Collapse
|
19
|
UCHIDA E, TAKAHASHI N, KOBAYASHI S, KAI K, IIDA S, KURATO T, HAMADA K, YASUHARA H. The Effect of Diltiazem and Verapamil on Hepatic Microsomal Drug Metabolizing Enzymes in Rat. ACTA ACUST UNITED AC 1991. [DOI: 10.15369/sujms1989.3.27] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
20
|
Hempenius J, Staal B, Jeuring HJ, Mensink CK, Jonkman JHG. Determination of Debrisoquine and 4-Hydroxydebrisoquine in Human Urine by High Performance Liquid Chromatography and Fluorescence Detection. ACTA ACUST UNITED AC 1990. [DOI: 10.1080/01483919008048980] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
21
|
Wanwimolruk S, Ferry DG. Rapid High-Performance Liquid Chromatographic Method for the Analysis of Debrisoquine and 4-Hydroxydebrisoquine in Urine without Derivatization. ACTA ACUST UNITED AC 1990. [DOI: 10.1080/01483919008049225] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
22
|
Capucci A, Boriani G, Marchesini B, Strocchi E, Tomasi L, Balducelli M, Frabetti L, Ambrosioni E, Magnani B. Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy. Cardiovasc Drugs Ther 1990; 4:281-7. [PMID: 2285622 DOI: 10.1007/bf01857646] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
We evaluated the antiarrhythmic efficacy and the minimal effective concentrations of propafenone and its metabolite 5-hydroxy-propafenone during a) acute intravenous infusion (1.5 mg/kg in bolus followed by 45 minutes infusion), b) an acute oral single-dose test (450 mg), and c) 14-day chronic therapy (300 mg tid) followed by a washout. Oxidative metabolism was assessed by a debrisoquine oral test in every patient. Eleven patients with stable ventricular premature beats (VPBs) greater than or equal to 300/hr and Lown class greater than or equal to 3 completed the study. The main results emphasized a certain discrepancy between the clinical effect of the acute intravenous infusion (efficacy in 5 out of 11 patients) and of the acute oral test and chronic therapy (efficacy in 11/11), with a time lag of the ECG changes during the acute intravenous infusion. The minimal effective concentrations were lower after acute oral administration compared with chronic treatment both for propafenone (200 +/- 189 ng/ml vs. 492 +/- 530 ng/ml; p less than 0.05) and for 5-hydroxy-propafenone (82 +/- 40 ng/ml vs. 149 +/- 80 ng/ml; p less than 0.02). A linear correlation was demonstrated between drug/metabolite ratios of propafenone and debrisoquine, either after acute oral (r = 0.91) or after chronic administration (r = 0.84). The pharmacokinetics of propafenone was nonlinear and showed wide interindividual variations.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- A Capucci
- Institute of Cardiovascular Diseases, University of Bologna, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Horai Y, Taga J, Ishizaki T, Ishikawa K. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population. Br J Clin Pharmacol 1990; 29:111-5. [PMID: 2297455 PMCID: PMC1380068 DOI: 10.1111/j.1365-2125.1990.tb03609.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
The study was aimed at defining the relationships among the oxidative capacities for three prototype drugs, metoprolol, debrisoquine and sparteine, used for assessing genetically determined polymorphism of drug oxidation in a Japanese population. Among 292 unrelated healthy Japanese subjects who had been defined as extensive (EMs, n = 291) or poor (PM, n = 1) metabolisers of metoprolol oxidation, 55 subjects (EMs = 54 and PM = 1) were selected. One PM of metoprolol oxidation was also identified as a PM not only of debrisoquine but also of sparteine, and no misclassification by the three phenotypic methods was observed. All three correlations among the metabolic ratios of the three test probes assessed by Spearman's rank test were highly significant (P less than 0.001). These findings indicate that in Japanese subjects the oxidation capacities of metoprolol, debrisoquine, and sparteine are closely related. It appears that in Japanese the polymorphic oxidation of the three drugs is co-regulated, either by the same enzyme or gene-controlling system.
Collapse
Affiliation(s)
- Y Horai
- Division of Clinical Pharmacology, Nihon University School of Medicine, Tokyo, Japan
| | | | | | | |
Collapse
|
24
|
|
25
|
Moncrieff J. Assay of debrisoquine and 4-hydroxydebrisoquine in urine by reversed-phase high-performance liquid chromatography using on-line sample clean-up on a standard isocratic chromatograph. JOURNAL OF CHROMATOGRAPHY 1988; 428:178-82. [PMID: 3170673 DOI: 10.1016/s0378-4347(00)83905-5] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- J Moncrieff
- Department of Pharmacology, Faculty of Medicine, University of Pretoria, Republic of South Africa
| |
Collapse
|
26
|
Keech AC, Harrison PM, McLean AJ. Simple extraction of atenolol from urine and its determination by high-performance liquid chromatography. JOURNAL OF CHROMATOGRAPHY 1988; 426:234-6. [PMID: 3384877 DOI: 10.1016/s0378-4347(00)81950-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- A C Keech
- Department of Clinical Pharmacology, Alfred Hospital, Prahran, Victoria, Australia
| | | | | |
Collapse
|
27
|
Chan K. Comparison of gas chromatographic and high-performance liquid chromatographic assays for the determination of debrisoquine and its 4-hydroxy metabolite in human fluids. JOURNAL OF CHROMATOGRAPHY 1988; 425:311-21. [PMID: 3372645 DOI: 10.1016/0378-4347(88)80035-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
A comparison of an established gas chromatographic assay for 4-hydroxydebrisoquine and debrisoquine and a modified high-performance liquid chromatographic assay was made. Both assays used guanoxan as the internal standard and required derivatization of all three compounds with acetylacetone at 96 degrees C for 2.5 h and subsequent ethereal extraction and cleaning steps before chromatographic analysis. For detailed pharmacokinetic studies the gas chromatographic assay was more sensitive in the measurement of low concentrations in plasma, but the liquid chromatographic assay was adequate for phenotyping the 4-hydroxylation of debrisoquine in a population. In the latter assay a mobile phase consisting of 70% methanol in water at pH 3.5 (adjusted with orthophosphoric acid containing 10 mM 1-pentanesulphonic acid was employed (flow-rate 1.5 ml/min) with a pre-column (C8) linked to a reversed-phase muBondapak C18 cartridge in a Z-module. The eluate was detected at 248 nm. With this assay it was observed that the buccal absorption of debrisoquine and 4-hydroxy-debrisoquine was affected by the pH of the buccal medium. This indicates that urinary pH may influence the excretion of both substances at high pH. The debrisoquine-to-4-hydroxydebrisoquine ratio may be dose-dependent.
Collapse
Affiliation(s)
- K Chan
- Department of Pharmacology, Faculty of Medicine, Chinese University of Hong Kong, Shatin
| |
Collapse
|
28
|
Meese CO, Fischer C, Eichelbaum M. Stereoselectivity of the 4-hydroxylation of debrisoquine in man, detected by gas chromatography/mass spectrometry. BIOMEDICAL & ENVIRONMENTAL MASS SPECTROMETRY 1988; 15:63-6. [PMID: 3349209 DOI: 10.1002/bms.1200150202] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
A stable isotope assay for the quantification of debrisoquine (1) and its major urinary metabolite 4-hydroxydebrisoquine (2) is described. The method consists of extractive derivatization of 1 and 2 by use of 1,3-diketones, chiral derivatization of the 4-hydroxy group of 2, and gas chromatography/negative ion chemical ionization mass spectrometry in the presence of deuterated analogues of 1 and 2. In comparison with synthetic R-(-)-2 and S-(+)-2 it is shown that in vivo benzylic 4-hydroxylation of 1 is highly stereoselective, leading predominantly to S-(+)-4-hydroxydebrisoquine (enantiomeric excess greater than or equal to 90%).
Collapse
Affiliation(s)
- C O Meese
- Dr Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart, FRG
| | | | | |
Collapse
|
29
|
Duche JC, Barre J, Tillement JP. Rapid liquid chromatographic determination of debrisoquine and its hydroxy metabolite in human urine to define hydroxylation phenotypes. JOURNAL OF CHROMATOGRAPHY 1987; 423:340-3. [PMID: 3443670 DOI: 10.1016/0378-4347(87)80361-4] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- J C Duche
- Laboratoire Hospitalo-Universitaire de Pharmacologie, Hôpital Intercommunal, Créteil, France
| | | | | |
Collapse
|
30
|
Meese CO, Thalheimer P, Eichelbaum M. High-performance liquid chromatographic method for the analysis of debrisoquine and its S-(+)- and R-(-)-hydroxy metabolites in urine. JOURNAL OF CHROMATOGRAPHY 1987; 423:344-50. [PMID: 3443671 DOI: 10.1016/0378-4347(87)80362-6] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- C O Meese
- Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart, F.R.G
| | | | | |
Collapse
|